On Nov. 30, 2020, Mateon Therapeutics announced that the India arm of ARTI-19 global study was on track to complete enrollment of the first 120 cohort by Dec 15, 2020, of which 78 patients had already been randomized. Interim analysis of the first 32 pts (8 WHO scale 2 and 24 WHO scale 4 on randomization) was performed.

Statistical significant Time dependent improvement in WHO scale following treatment with ARTIVedaTM+SOC versus SOC alone was observed.